Aduro Biotech Inc. (NASDAQ:ADRO)’s share price dropped 1.6% on Thursday . The company traded as low as $14.23 and last traded at $14.32, with a volume of 167,841 shares changing hands. The stock had previously closed at $14.56.

ADRO has been the subject of a number of analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective on shares of Aduro Biotech in a research report on Friday, August 5th. FBR & Co reissued a “buy” rating and issued a $34.00 price objective (up previously from $30.00) on shares of Aduro Biotech in a research report on Saturday, May 14th. Leerink Swann reissued a “buy” rating and issued a $48.00 price objective on shares of Aduro Biotech in a research report on Thursday, May 5th. Roth Capital reaffirmed a “buy” rating and set a $22.00 price target on shares of Aduro Biotech in a research report on Monday, July 11th. Finally, Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Aduro Biotech currently has a consensus rating of “Hold” and a consensus target price of $22.00.

The stock has a 50 day moving average of $14.40 and a 200-day moving average of $13.23. The firm’s market capitalization is $867.06 million.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.21. The business had revenue of $39 million for the quarter, compared to the consensus estimate of $25.24 million. The business’s revenue for the quarter was up 306.3% on a year-over-year basis. Analysts predict that Aduro Biotech Inc. will post ($1.39) EPS for the current year.

In other news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $15.18, for a total transaction of $379,500.00. Following the completion of the transaction, the insider now owns 12,500 shares in the company, valued at approximately $189,750. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC raised its stake in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.